| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Neurology, PVA/EPVA Neuroscience Research Center, Yale University School of Medicine, and the Rehabilitation Research Center, VA Healthcare Systems, West Haven, CT, USA
* To whom correspondence should be addressed. E-mail: stephen.waxman{at}yale.edu.
Axonal degeneration within the spinal cord contributes substantially to neurological disability in multiple sclerosis (MS). Thus neuroprotective therapies that preserve axons, so that they maintain their integrity and continue to function, might be expected to result in improved neurological outcome. Sodium channels are known to provide a route for sodium influx that can drive calcium influx, via reverse operation of the Na+/Ca2+ exchanger, after injury to axons within the CNS, and sodium channel blockers have been shown to protect CNS axons from degeneration following experimental anoxic, traumatic, and NO-induced injury. In this study we asked whether phenytoin, which is known to block sodium channels, can protect spinal cord axons from degeneration in mice with experimental allergic encephalomyelitis (EAE), which display substantial axonal degeneration and clinical paralysis. We demonstrate that the loss of dorsal corticospinal tract (63%) and dorsal column (cuneate fasciculus) (43%) axons in EAE is significantly ameliorated (corticospinal tract: 28%; cuneate fasciculus: 17%) by treatment with phenytoin. Spinal cord compound action potentials (CAP) were significantly attenuated in untreated-EAE, whereas spinal cords from phenytoin-treated EAE had robust CAPs, similar to those from phenytoin-treated control mice. Clinical scores in phenytoin-treated EAE at 28 days were significantly improved (1.5, i.e. minor righting reflex abnormalities) compared to untreated EAE (3.8, i.e. near-complete hindlimb paralysis). Our results demonstrate that phenytoin has a protective effect in vivo on spinal cord axons, preventing their degeneration, maintaining their ability to conduct action potentials, and improving clinical status in a model of neuroinflammation.
This article has been cited by other articles:
|
|
 |
|
  S. Bittner, S. G. Meuth, K. Gobel, N. Melzer, A. M. Herrmann, O. J. Simon, A. Weishaupt, T. Budde, D. A. Bayliss, M. Bendszus, et al. TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system Brain, September 1, 2009; 132(9): 2501 - 2516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Carrithers, G. Chatterjee, L. M. Carrithers, R. Offoha, U. Iheagwara, C. Rahner, M. Graham, and S. G. Waxman Regulation of Podosome Formation in Macrophages by a Splice Variant of the Sodium Channel SCN8A J. Biol. Chem., March 20, 2009; 284(12): 8114 - 8126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Carrithers, S. Dib-Hajj, L. M. Carrithers, G. Tokmoulina, M. Pypaert, E. A. Jonas, and S. G. Waxman Expression of the Voltage-Gated Sodium Channel NaV1.5 in the Macrophage Late Endosome Regulates Endosomal Acidification J. Immunol., June 15, 2007; 178(12): 7822 - 7832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Eftekharpour, S. Karimi-Abdolrezaee, J. Wang, H. El Beheiry, C. Morshead, and M. G. Fehlings Myelination of Congenitally Dysmyelinated Spinal Cord Axons by Adult Neural Precursor Cells Results in Formation of Nodes of Ranvier and Improved Axonal Conduction J. Neurosci., March 28, 2007; 27(13): 3416 - 3428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Smith Axonal protection in multiple sclerosis--a particular need during remyelination? Brain, December 1, 2006; 129(12): 3147 - 3149. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Black, S. Liu, B. C. Hains, C. Y. Saab, and S. G. Waxman Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE Brain, December 1, 2006; 129(12): 3196 - 3208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Frohman, M. K. Racke, and C. S. Raine Multiple sclerosis--the plaque and its pathogenesis. N. Engl. J. Med., March 2, 2006; 354(9): 942 - 955. [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Hains and S. G. Waxman Neuroprotection by Sodium Channel Blockade with Phenytoin in an Experimental Model of Glaucoma Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 4164 - 4169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, et al. Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions Arch Neurol, September 1, 2005; 62(9): 1345 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Waxman Sodium channel blockers and axonal protection in neuroinflammatory disease Brain, January 1, 2005; 128(1): 5 - 6. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Bechtold, X. Yue, R. M. Evans, M. Davies, N. A. Gregson, and K. J. Smith Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide Brain, January 1, 2005; 128(1): 18 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Craner, J. Newcombe, J. A. Black, C. Hartle, M. L. Cuzner, and S. G. Waxman Molecular changes in neurons in multiple sclerosis: Altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger PNAS, May 25, 2004; 101(21): 8168 - 8173. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
